Advanced Urology Among First in the Nation to Treat  Advanced Prostate Cancer Patients with PROVENGE

Advanced Urology is one of the first urology practices in the nation—and Colorado—to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. Provenge was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.

Provenge is designed to stimulate a patient's immune system to target prostate cancer cells. Each dose is manufactured specifically for the patient using his own immune cells.

The process of making Provenge involves introducing a patient's immune cells to a protein that functions as a prostate-cancer associated antigen. An antigen is a substance that causes the body to react with an immune response. This process activates the patient's immune cells against prostate cancer cells to help the immune system better fight the disease.

A complete course of Provenge is three infusions, typically administered approximately two weeks apart. In general, side effects from treatment have been reported as mild or moderate.

Is Provenge Right For You?

Provenge may be a suitable treatment option for you, if the following are true:

• You are on hormone therapy and have rising prostate-specific antigen (PSA) levels
• Your doctor has confirmed that your cancer has spread from the prostate to other places, such as your bones
• You are not taking narcotics for cancer-related pain

Talk to Your Doctor

To learn more about Provenge for prostate cancer treatment, including if it may be an appropriate treatment option for you, please contact our office by calling 303-695-6106. When speaking to your urologist about Provenge, you may ask how it will fit into your overall prostate cancer treatment plan, what are the treatment steps, and what you can expect during Provenge treatment. For information about insurance coverage of Provenge, please visit Dendreon's Provenge site>>

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.